<?xml version='1.0' encoding='utf-8'?>
<document id="30447923"><sentence text="Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions." /><sentence text="Patients with cancer are at high risk of developing venous thromboembolism (VTE)" /><sentence text=" Although the recommended low molecular weight heparins (LMWHs) are more effective than vitamin K antagonists in treating VTE in patients with cancer, they have limitations and contraindications"><entity charOffset="88-97" id="DDI-PubMed.30447923.s3.e0" text="vitamin K" /></sentence><sentence text=" Direct oral anticoagulants (DOACs) circumvent some of these limitations" /><sentence text=" Here, DOAC use for VTE treatment in patients receiving anticancer therapy is reviewed, focusing on metabolic and elimination pathways, potential drug-drug interactions and practical considerations" /><sentence text=" DOACs are typically substrates of the cytochrome P450-based metabolic pathways and/or ATP-binding cassette transporters" /><sentence text=" Although many cancer therapies influence these pathways, only a minority of these drugs interact with DOACs" /><sentence text=" Phase III DOAC trials provided encouraging safety and efficacy data for their use in cancer-associated thrombosis" /><sentence text=" Furthermore, numerous ongoing DOAC trials strive to gain a better understanding of the treatment of cancer-associated thrombosis and continue to support a role for DOACs in this setting" /><sentence text="" /></document>